The British government, pharmaceutical companies, and a research charity establish a venture capital fund.
Motor neurons may be susceptible to ALS because they lack a chaperone that folds SOD1.
Researchers found inherited recessive or dominant de novo mutations in people with sporadic ALS whose parents did not have the disease.
Approximately 4 percent of familial ALS cases may be due to TBK1 mutations.
A novel assay detected two strains of human SOD1 in mice expressing the protein. They differed from those that formed in vitro. Researchers hope to use the technique to identify strains of other problem proteins as well.
Microbleeds in the brain portend either stroke or cardiovascular events, depending on where they occur.
Treatments targeting the main pathological protein of Parkinson’s disease are moving toward the clinic, with two immunotherapies passing Phase 1 safety benchmarks.
Epigenetic changes in the C9ORF72 promoter do not prevent disease, but they do decelerate brain atrophy and memory loss.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
A screen in round worms identifies a novel mechanism for degradation of toxic proteins.
By dampening translation, these tiny RNAs keep protein levels from fluctuating wildly.
The highs and lows of cerebrospinal fluid Aβ and PET amyloid imaging don't necessarily agree.
The FDA last Friday followed the recommendation of its advisory panel last month and approved memantine for use in moderate to severe AD...
Scientists at last month’s Society for Neuroscience conference in Chicago confirmed the vampire principle, whereby young blood keeps an aging organism vigorous...
Peptides made from D-amino acids bind to Aβ oligomers and trigger their removal from the brain. Some appear poised to enter Phase 1.
No filters selected